Analyst Ratings for [CYTK] Cytokinetics, Incorporated

2/7/25	Initiated	Buy	X
CYTK Cytokinetics Citigroup
$86
1/22/25	Initiated	Buy		X
CYTK Cytokinetics Stifel
$80
11/8/24	Initiated	Outperform		X
CYTK Cytokinetics RBC Capital Mkts
$80
8/13/24	Downgrades	Buy Neutral	X
CYTK Cytokinetics Goldman
$85 $60
1/24/24	Downgrades	Buy Neutral		X
CYTK Cytokinetics UBS
$61 $92
1/5/24	Downgrades	Overweight Eq-Weight		X
CYTK Cytokinetics Morgan Stanley
$60 $90
11/9/23	Initiated	Buy	X
CYTK Cytokinetics Goldman
$50
11/7/23	Initiated	Buy		X
CYTK Cytokinetics B. Riley Securities
$66
8/15/23	Initiated	Outperform		X
CYTK Cytokinetics SVB Securities
$58
2/17/23	Initiated	Neutral	X
CYTK Cytokinetics BofA Securities
$49
12/23/22	Reiterated	Buy		X
CYTK Cytokinetics Needham
$60 $58
12/20/22	Initiated	Buy		X
CYTK Cytokinetics Truist
$60
10/11/22	Initiated	Buy	X
CYTK Cytokinetics UBS
$80
12/22/21	Initiated	Outperform		X
CYTK Cytokinetics Oppenheimer
$55
12/10/21	Initiated	Overweight		X
CYTK Cytokinetics JP Morgan
$58
10/7/21	Initiated	Buy	X
CYTK Cytokinetics Jefferies
$75
3/12/21	Initiated	Outperform		X
CYTK Cytokinetics Wolfe Research
$50
2/18/21	Initiated	Overweight		X
CYTK Cytokinetics Barclays
$28
1/20/21	Reiterated	Buy	X
CYTK Cytokinetics H.C. Wainwright
$22 $41
9/21/18	Initiated	Overweight		X
CYTK Cytokinetics Cantor Fitzgerald
9/10/18	Resumed	Equal-Weight		X
CYTK Cytokinetics Morgan Stanley
$10

CYTK Cytokinetics, Incorporated

Quotes: Barrons • SeekingAlpha • NASDAQ • Bloomberg • WSJ

Cytokinetics, Incorporated is a late-stage biopharmaceutical company. The Company is focused on discovering, developing and commercializing first-in-class muscle activators as potential treatments for debilitating diseases in which muscle performance is compromised and/or declining. It is focused on the discovery and development of small molecule therapeutics that modulate muscle function for the treatment of serious diseases and medical conditions. Its drug candidates, which are in clinical development include tirasemtiv, CK-2127107 and omecamtiv mecarbil. Its tirasemtiv and CK-2127107 are skeletal muscle troponin activators. It is developing tirasemtiv drug candidate for the treatment of Amyotrophic lateral sclerosis (ALS). The Company is developing CK-2127107 for the potential treatment of spinal muscular atrophy, chronic obstructive pulmonary disease and ALS. The Omecamtiv mecarbil is a cardiac muscle myosin activator, which is being evaluated for the treatment of heart failure.